Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 677 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single intravenous doses of placebo Clear all
Withdrawn Phase 2 Interventional

Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients

NCT00482287
View directory record Official record
Conditions
Hypotension, Cardiopulmonary Bypass
Interventions
MTR105
Drug
Lead sponsor
Meditor Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 19, 2026, 9:34 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

NCT04411628
View directory record Official record
Conditions
COVID-19
Interventions
LY3819253, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 19, 2026, 9:34 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Single and Multiple Ascending Dose Study of MT-251

NCT07423299
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MT-251
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of PRX002 in Healthy Subjects

NCT02095171
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PRX002, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304
View directory record Official record
Conditions
RSV Illness in ≤12 Months of Participants
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 12 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Tucson, Arizona • Long Beach, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healthy Adults

NCT03603665
View directory record Official record
Conditions
Botulism
Interventions
NTM-1633, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants

NCT02008279
View directory record Official record
Conditions
Healthy
Interventions
100 mg CNTO 3157, 300 mg CNTO 3157, 600 mg CNTO 3157, Placebo
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease

NCT02459886
View directory record Official record
Conditions
Parkinson's Disease, Healthy
Interventions
BIIB054, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
40 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hallandale, Florida • Oviedo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

NCT01995383
View directory record Official record
Conditions
Atherosclerosis
Interventions
LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

NCT05305222
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

NCT01764737
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Cullman, Alabama • Aurora, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 19, 2026, 9:34 AM EDT
Terminated Phase 1 Interventional Results available

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

NCT01483183
View directory record Official record
Conditions
Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Interventions
OPC-108459, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Hollywood, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

NCT05721287
View directory record Official record
Conditions
Pain, Acute Pain
Interventions
SBS-1000, Placebo
Drug
Lead sponsor
Sparian Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

NCT00679263
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Oct 19, 2026, 9:34 AM EDT
Recruiting Early Phase 1 Interventional

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

NCT03849443
View directory record Official record
Conditions
Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions
Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Results available

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

NCT02542605
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo, PACAP-38 Challenge Agent
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 19, 2026, 9:34 AM EDT
Terminated Early Phase 1 Interventional

Effect of Ketamine on Fatigue Following Cancer Therapy

NCT02317341
View directory record Official record
Conditions
Cancer, Fatigue, Ketamine
Interventions
Ketamine, Placebo (saline), Midazolam, Midazolam(placebo)
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

NCT01565681
View directory record Official record
Conditions
Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions
ASP1240, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout

NCT00663169
View directory record Official record
Conditions
Arthritis, Gouty
Interventions
canakinumab, dexamethasone, placebo matching canakinumab, placebo matching dexamethasone
Biological · Drug · Other
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Birmingham, Alabama • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

NCT02593331
View directory record Official record
Conditions
Insulin Resistance
Interventions
BFKB8488A, Placebo
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

NCT04999527
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DISC-0974, Placebo
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 2 Interventional

Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After Bunionectomy

NCT00293631
View directory record Official record
Conditions
Bunionectomy, Orthopedic Surgery
Interventions
Lornoxicam 8 mg, Lornoxicam 16 mg, Ketorolac 30 mg, Placebo
Drug
Lead sponsor
POZEN
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 19, 2026, 9:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

NCT05411588
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-07275315, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Lake Forest, California • Tustin, California • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 19, 2026, 9:34 AM EDT